Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors

Journal of Medicinal Chemistry

Volumn 49, Issue 21, 2006, Pages 6273-6282

  Hu, Laixing ^a,b   Li, Zhuo Rong ^b   Li, Yan ^c   Qu, Jinrong ^c   Ling, Yi He ^d   Jiang, Jian Dong ^b   Boykin, David W ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 ETHYL N (3,4,5 TRIMETHOXYPHENYL)CARBAZOLE 3 SULFONAMIDE; ANTIMITOTIC AGENT; CARBAZOLE DERIVATIVE; COMBRETASTATIN A4; PROTEIN BCL 2; PROTEIN P53; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE M PHASE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; LEUKEMIA CELL; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIMITOTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARBAZOLES; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750098235     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060546h     Document Type: Article

References (43)

1. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4, 253-265.
2. Jiang, J. D.; Wang, Y.; Roboz, J.; Strauchen, J.; Holland, J. F.; Bekesi, J. G. Inhibition of microtubule assembly in tumor cells by 3-bromo-acetylamino benzoylurea, a new cancericidal compound. Cancer Res. 1998, 58, 2126-2133.
3. Dumontet, C.; Sikic, B. I. Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport and cell death. J. Clin. Oncol. 1999, 17, 1061-1070.
4. Wood, K. W.; Cornwell, W. D.; Jackson, J. R. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol. 2001, 1, 370-7.
5. (a) Sarli, V.; Giannis, A. Inhibitors of mitotic kinesins: next-generation antimitotics. ChemMedChem 2006, 1, 293-298.
6. (b) Tao, W.; South, V. J.; Zhang, Y.; Davide, J. P.; Farrell, L.; Kohl, N. E.; Sepp-Lorenzino, L.; Lobell, R. B. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005, 8, 49-59.
7. (c) Duhl, D. M.; Renhowe, P. A. Inhibitors of kinesin motor proteins-research and clinical progress. Curr. Opin. Drug Discover Dev. 2005, 8, 431-436.
8. (a) Ling, Y. H.; Liebes, L.; Jiang, J. D.; Holland, J. F.; Elliott, P. J.; Adams, J.; Muggia, F. M.; Perez-Soler, R. Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. 2003, 9, 1145-1154.
9. (b) Ling, Y. H.; Liebes, L.; Ng, B.; Buckley, M.; Elliott, P. J.; Adams, J.; Jiang, J. D.; Muggia, F. M.; Perez-Soler, R. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther. 2002, 1, 841-849.
10. (a) Pettit, G. R.; Cragg, G. M.; Singh, S. B. Antineoplastic agents, 122. Constituents of Combretum caffrum. J. Nat. Prod. 1987, 50, 386-391.
11. (b) Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45, 209-211.
12. Young, S. L.; Chaplin, D. J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin. Invest. Drugs 2004, 13, 1171-1182.
13. Dorr, R. T.; Dvorakova, K.; Snead, K.; Alberts, D. S.; Salmon, S. E.; Pettit, G. R. Antitumor activity of combretastatin-A4-phosphate, a natural product tubulin inhibitor. Invest. New Drugs 1996, 14, 131-137.
14. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumor blood vessels. Nat. Rev. Cancer 2005, 5, 423-435.
15. (b) Tozer, G. M.; Kanthou, C.; Parkins, C. S.; Hill, S. A. The Biology of the combretastatins as tumour targeting agents. Int. J. Exp. Pathol. 2002, 83, 21-38.
16. Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A. K.; Lin, C. M.; Hamel, E. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med. Chem. 1991, 34, 2579-2588.
17. Cushman, M.; Nagarathnam, D.; Gopal, D.; He, H.-M.; Lin, C. M.; Hamel, E. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5- trimethoxyphenyl) ethene as potential cytotoxic and antimitotic agents. J. Med. Chem. 1992, 35, 2293-2306.
18. (a) Nam, N. H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem. 2003, 10, 1697-1722.
19. (b) Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical design of antimitotic agents based on combretastatins. Curr. Pharm. Des. 2005, 11, 1655-1677.
20. (a) Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J. Med. Chem. 1998, 41, 3022-3032.
21. (b) Tron, G. C.; Pagliai, F.; Grosso, E. D.; Genazzani, A. A.; Sorba, G. Synthesis and cytotoxic evaluation of combretafurazans, J. Med. Chem. 2005, 48, 3260-3268.
22. (c) LeBlanc, R.; Dickson, J.; Brown, T.; Stewart, M.; Pati, H. N.; VanDerveer, D.; Arman, H.; Harris, J.; Pennington, W.; Holt, H. L.; Lee, M. Synthesis and cytotoxicity of epoxide and pyrazole analogues of the combretastatins. Bioorg. Med. Chem. 2005, 13, 6025-6034.
23. (d) Perez-Melero, C.; Maya, A. B. S.; Rey, B. D.; Pelaez, R.; Caballero, E.; Medarde M. A new family of quinolone and quinoxaline analogues of combretastatins. Bioorg. Med. Chem. Lett. 2004, 14, 3771-3774.
24. (e) Simoni, D.; Romagnoli, R.; Baruchello, R.; Rondanin, R.; Rizzi, M.; Pavani, M. G.; Alloatti, D.; Giannini, G.; Marcellini, M.; Riccioni, T.; Castorina, M.; Guglielmi, M. B.; Bucci, F.; Carminati, P.; Pisano, C. Novel combretastatin analogues endowed with antitumor activity. J. Med. Chem. 2006, 49, 3143-3152.
25. (a) Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C. T. Auticancer and antiviral sulfonamides. Curr. Med. Chem. 2003, 10, 925-953.
26. (b) Casini, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targets 2002, 2, 55-75.
27. (a) Yoshino, Y.; Ueda, N.; Niijima, J.; Sugumi, H.; Kotake, Y.; Koyanagi, N.; Yoshimatsu, K.; Asada, M.; Watanabe, T.; Nagasu, T.; Tsukahara, K.; Iijima, A.; Kitoh, K. Novel sulfonamides as potential, systemically active antitumor agents. J. Med. Chem. 1992, 35, 2496-2497.
28. (b) Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of action of E7010: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997, 57, 3208-3213.
29. (c) Koyanagi, N.; Nagasu, T.; Fujita, F.; Watanabe, T.; Tsukahara, K.; Funahashi, Y.; Fujita, M.; Taguchi, T.; Yoshino, H.; Kitoh, K. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res. 1994, 54, 1702-1706.
30. (d) Segretti, J. A.; Polakowski, J. S.; Koch, K. A.; Marsh, K. C.; Bauch, J. L.; Rosenber, S. H.; Sham, H. L.; Cox, B. F.; Reinhart, G. A. Tumor selective anti effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother. Pharmacol. 2004, 54, 273-281.
31. Shan, B.; Medina, J. C.; Santha, E.; Frankmoelle, W. P.; Chou, T.-C.; Learned, R. M.; Narbut, M. R.; Stott, D.; Wu, P.; Jaen, J. C.; Rosen, T.; Timmermans, P. B. M. W. M.; Beckmann, H. Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 5686-5691.
32. Medina, J. C. Preparation of benzenesulfonamides and benzamides regulating low-density lipoprotein (LDL) receptor expression and of inhibiting abnormal cell proliferation. WO 9936391, 1999.
33. (a) Li, Q.; Sham, H.; Woods, K. W.; Steiner, B. A.; Gwaltney, S. L., II; Barr, K. J.; Imade, H. M.; Rosenberg, S. Preparation of sulfonamides as cell proliferation inhibitors. U.S. 6521658, 2003.
34. (b) Prinz, H. Recent advances in the field of tubulin polymerization inhibitors. Expert Rev. Anticancer Ther. 2002, 2, 695-708.
35. Caulfield, T.; Cherrier, M.; Combeau, C.; Mailliet, P. Substituted carbazoles as tubulin polymerization inhibitors and their use for the treatment of cancer. EP 1253141, 2002.
36. 2 receptor antagonists. 1. bicyclo[2.2.1]heptane derivatives. J. Med. Chem. 2003, 46, 2436-2445.
37. Bellamy, F. D.; Ou, K. Selective reduction of aromatic nitro compounds with stannous chloride in nonacidic and nonaqueous medium. Tetrahedron Lett. 1984, 25, 839-842.
38. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: Present and future directions. J. Med. Chem. 2006, 49, 3033-3044.
39. Wang, L. G.; Liu, X. M.; Kreis, W.; Budman, D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 1999, 44, 355-361.
40. Petrov, V.; Petrova, V.; Girichev, G. V.; Oberhammer, H.; Giricheva, N. I.; Ivanov, S. Molecular structure and conformations of benzene-sulfonamide: gas electron diffraction and quantum chemical calculations. J. Org. Chem. 2006, 71, 2952-2956.
41. Proshechkina, T. I.; Shishkina, V. I.; Pushkareva, Z. V.; Radtsev, V. S.; Popova, E. N. Peculiarities of composition and chemical conversion of carbazole and its derivatives. XXVIII. The synthesis of sulfamide compounds in the carbazole series. Khim.-Farm. Zh. 1968, 2, 24-27.
42. Rubenstein, S. M.; Baichwal, V.; Beckmann, H.; Clark, D. L.; Frankmoelle, W.; Roche, D.; Santha, E.; Schwender, S.; Thoolen, M.; Ye, Q.; Jaen, J. C. Hydrophilic, prodrug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J. Med. Chem. 2001, 44, 3599-3605.
43. Yagi, M. J.; Bekesi, J. G. Evaluation of p-F-Phe-m-bis-(2-chloroethyl) amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia. Cancer Chemother. Pharmacol. 1990, 26, 215-220.